Rockwell Medical (NASDAQ:RMTI) issued its quarterly earnings results on Thursday, March 15th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.05), Bloomberg Earnings reports. Rockwell Medical had a negative net margin of 45.24% and a negative return on equity of 61.67%. The business had revenue of $14.84 million for the quarter, compared to analysts’ expectations of $13.20 million. During the same period last year, the business earned ($0.10) earnings per share. The company’s revenue was up 10.5% on a year-over-year basis.
Rockwell Medical stock traded down $0.26 during trading hours on Thursday, reaching $5.30. 248,008 shares of the company’s stock were exchanged, compared to its average volume of 266,692. The company has a market cap of $285.76, a price-to-earnings ratio of -10.39 and a beta of 2.04. Rockwell Medical has a 1-year low of $4.84 and a 1-year high of $8.98.
A number of research analysts recently issued reports on RMTI shares. Zacks Investment Research raised shares of Rockwell Medical from a “sell” rating to a “hold” rating in a research report on Thursday, November 30th. BidaskClub upgraded shares of Rockwell Medical from a “sell” rating to a “hold” rating in a research note on Friday, December 15th. Finally, ValuEngine lowered shares of Rockwell Medical from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd.
TRADEMARK VIOLATION NOTICE: This piece of content was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://ledgergazette.com/2018/03/23/rockwell-medical-rmti-posts-earnings-results-misses-estimates-by-0-05-eps.html.
Rockwell Medical Company Profile
Rockwell Medical, Inc (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process.
Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with MarketBeat.com's FREE daily email newsletter.